Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308594 | 0.84 | SIGMAR1 (0.45) | SIGMAR1GNAI3GNAO1GNAI1SLC6A2 | |
| SCHEMBL26760234 | 0.82 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27666670 | 0.81 | SIGMAR1 (0.41) | SIGMAR1GNAI3GNAO1GNAI1SLC6A2 | |
| SCHEMBL21574389 | 0.80 | SIGMAR1 (0.43) | SIGMAR1GNAI3GNAO1GNAI1SLC6A2 | |
| SCHEMBL26760915 | 0.80 | SIGMAR1 (0.43) | SIGMAR1GNAI3GNAO1GNAI1SLC6A2 | |
| SCHEMBL22702329 | 0.79 | SIGMAR1 (0.42) | SIGMAR1GNAI3GNAO1GNAI1SLC6A2 | |
| SCHEMBL369682 | 0.78 | GNAO1 (0.43) | SIGMAR1GNAI3GNAO1GNAI1SLC6A2 | |
| SCHEMBL27645441 | 0.77 | SIGMAR1 (0.41) | SIGMAR1GNAI3GNAO1GNAI1SLC6A2 | |
| SCHEMBL18761564 | 0.77 | GNAO1 (0.46) | SIGMAR1GNAI3GNAO1GNAI1SLC6A2 | |
| SCHEMBL22019451 | 0.77 | GNAO1 (0.46) | SIGMAR1GNAI3GNAO1GNAI1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501851-B1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | NITTO DENKO AVECIA INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8093397-B2 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1575975-B1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA BIOTECHNOLOGY INC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-7635772-B2 | Process for the preparation of oligonucleotides | AVECIA BIOTECHNOLOGY INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090085006-A1 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7501505-B2 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7476709-B2 | Process for preparing oligonucleotides | AVECIA BIOTECHNOLOGY INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7247720-B2 | Phosphitylation process | AVECIA BIOTECHNOLOGY INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1554300-B1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060149052-A1 | Process for the preparation of oligonucleotides | AVECIA LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-20060036028-A1 | Process for preparing oligonucleotides | NITTO DENKO AVECIA, INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1404696-B1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1575975-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | Avecia Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| EP-1554300-A1 | PHOSPHITYLATION PROCESS | Avecia Biotechnology, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1501851-A1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | Avecia Limited (GB) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004055036-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004035599-A1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1404696-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | Avecia Biotechnology, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003091267-A1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003004512-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036028-A1 | Process for preparing oligonucleotides | RTCB, POLRMT, POLM | SIGMAR1 4139/4885GNAI3 4244/4885GNAO1 3184/4885 |
| US-20060149052-A1 | Process for the preparation of oligonucleotides | CPSF7, CPSF1, CPSF6 | SIGMAR1 4216/4885GNAI3 4758/4885GNAO1 4375/4885 |
| US-20090085006-A1 | Activators for oligonucleotide synthesis | MED12, ORC3, NOP2 | SIGMAR1 83/4885GNAI3 1615/4885GNAO1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.